ABSTRACT
Objective To investigate the effects of meglumine adenosine cyclophosphate administrated before percutaneous coronary intervention (PCI) on curative efficacy, cardiac function and oxidative stress in patients with acute myocardial infarction (AMI).Methods118 patients of AMI meeting the inclusion criteria were selected as research objects.According to therapeutic schemes, those patients were divided into the control group (n=52) and the observation group (n=66).Before PCI, the control group was given conventional treatments.Besides that, the observation group was given meglumine adenosine cyclophosphate.Then, the curative efficacy, indices of cardiac function and oxidative stress were compared.ResultsAfter the treatments, the observation group had higher rates of ST decrease (>50%), thrombolysis in myocardial infarction(TIMI)3 grade (90.9% vs76.9%,84.8% vs 69.2%, P<0.05) and lower peak concentration of creatine kinase isoenzyme(CK-MB), cardiac troponin(cTn)I[(140.6±26.5) U/L比(193.7±30.8) U/L,(1.92±0.24)μg/L 比(2.71±0.32) μg/L,P<0.05].After the treatment, indices of stroke volume (SV), cardiac output (CO) and left ventricular ejection function (LVEF) which reflect cardiac function in the observation group were statistically higher than those in the control group [(57.26±9.37)mL vs.(52.16±9.15)mL,(5.23±1.17) L/min vs(4.49±1.12)L/min,(0.62±0.12) % vs.(0.51±0.15)%,P<0.05].24 hours after PCI, as to oxidative stress, the observation group had a statistically lower level of malondialdehyde(MDA) and higher level of superoxide dismutase[(4.39±0.43)nmol/L vs.(6.45±0.46) nmol/L, [(87.12±10.34)U/mL vs.(68.29±9.48)U/mL), P<0.05].ConclusionMeglumine adenosine cyclophosphate administrated before PCI is effective for patients with AMI.And it can significantly improve cardiac function and alleviate oxidative stress.
ABSTRACT
OBJECTIVE:To investigate clinical efficacy and safety of meglumine adenosine cyclophosphate in the treatment of acute myocardium infarction. METHODS:A total of 80 patients with acute myocardium infarction in our hospital during May 2015-Jan. 2016 were selected and divided into control group and observation group according to random number table,40 cases in each group. Control group was given conventional treatment. Observation group was additionally given Meglumine adenosine cyclo-phosphate injection 120 mg added into 5% Glucose injection 250 mL,ivgtt,qd,on the basis of control group. Both groups re-ceived treatment for 7 d. Clinical efficacies as well as the levels of serum hs-CRP and NT-proBNP before and after treatment were observed in 2 groups,and the occurrence of ADR was compared between 2 groups. RESULTS:Total response rate of observation group(92.50%)was significantly higher than that of control group(75.00%),with statistical significance(P0.05). After treat-ment,the serum levels of hs-CRP and NT-proBNP in 2 groups were decreased significantly,and the observation group was signifi-cantly lower than the control group,with statistical significance(P0.05). CONCLUSIONS:Meglumine adenosine cyclophosphate shows significant therapeutic efficacy for acute myocardium infarction,reduces serum levels of hs-CRP and NT-proBNP significantly with good safety.
ABSTRACT
Objective: To explore therapeutic effect of meglumine adenosine cyclophosphate (MAC) combined enalapril on patients with chronic heart failure (CHF).Methods: A total of 90 CHF patients treated in our hospital were selected and randomly divided into routine treatment group (n=45) and combined treatment group (n=45, received MAC combined enalapril therapy based on routine treatment).Plasma brain natriuretic peptide (BNP), red cell distribution width (RDW), left ventricular ejection fraction (LVEF), stroke volume (SV), cardiac output (CO) and heart function improvement were compared between two groups before and after treatment.Results: After four-week treatment, compared with before treatment, there were significant improvements in all indexes in both groups after treatment, P<0.05 or <0.01.Compared with routine treatment group after treatment,there was sighificantly improvement in marked inprovement rate(22.2% vs.40.0%,P=0.004)in combined treatment group;there were significant reductions in levels of BNP [(489.8±268.4) pg/ml vs.(332.5±253.8) pg/ml], RDW [(14.01±2.34)% vs.(13.02±2.11)%] (P<0.05 or <0.01), and significant rise in LVEF [(43.6±8.2)% vs.(47.8±7.3)%], SV [(45.9±5.69)ml vs.(54.2±6.12)ml] and CO [(4.23±0.55)L/min vs.(4.80±0.54)L/min] in combined treatment group, P<0.05 or <0.01.Conclusion: MAC combined enalapril can significantly reduce levels of BNP and RDW, and possess significant therapeutic effect in patients with chronic heart failure.
ABSTRACT
Objective To investigate the clinical curative effect and safety of Shenmai combined with meglu-mine adenosine cyclophosphate in the treatment of chronic heart failure.Methods 118 patients with chronic heart failure were selected as the research subjects.They were randomly divided into control group and observation group, 59 cases in each group.The patients in the control group received routine comprehensive treatment,the observation group was given intravenous Shenmai injection 50mL,1 /d,meglumine adenosine cyclophosphate injection 120mg, 250mL 5% glucose injection intravenous drip note,the 1 time /d,7d for a course of treatment.Two groups of patients received a total of 2 courses of treatment.Before and after treatment,left ventricular ejection fraction (LVEF)was detected by cardiac ultrasound,and the brain natriuretic peptide (BNP)level in patients was measured.The total effective rate of the two groups was analyzed.Results Before treatment,LVEF of the control group and the observa-tion group were (32.19 ±5.72)%,(32.50 ±6.01 )%.After treatment,LVEF of control group was (36.62 ± 4.13)%,LVEF indexes in the observation group was (42.09 ±5.52)%,LVEF increased significantly in the two groups,but that in the observation group was higher than that of the control group (t =-3.882,P =0.017),the difference was statistically significant.Before treatment,BNP index of the observation group and the control group were (485.16 ±206.15 )pg/mL,(489.11 ±178.96)pg/mL,after treatment,BNP level of the observation group was (159.29 ±93.62)pg/mL,BNP level in the control group was (322.36 ±156.58)pg/mL,BNP in the observation group was significantly lower than that of the control group(t =-7.443,P =0.000).24 cases in the observation group after treatment,effective in 30 cases,the total effective rate was 91.53%,which was significantly higher than 76.27% of the control group (χ2 =9.524,P =0.003).No obvious adverse reactions or allergic reaction etc.were observed in the observation group.Conclusion The therapeutic effect of combination of Shenmai injection and meglumine in the treatment of chronic heart failure is accurate,it can significantly improve cardiac function,and has high safety,and without adverse reaction reports,it is worthy of the clinical application and popularization.
ABSTRACT
Objective To study the compatibility stability of Shuxuening injection and meglumine adenosine cyclophosphate injection . Methods The compatibility program of Shuxuening injection and meglumine adenosine cyclophosphate injection was optimized by orthogonal experimental design, with the main components total flavone of Ginkgo biloba ( quercetin, kaempferide and isorhamnetin as control substance) and Ginkgo lactone ( ginkgolide A, B and C as control substance) of Shuxuening injection, the principal components adenosine cyclophosphate ( denosine cyclophosphate as control substance) of meglumine adenosine cyclophosphate injection as the main index to draw calibration curve, select temperature (A), illumination (B),storage time (C) and solvent (D) as factor, the change of insoluble particles and pH in solution was studied also.Results The optimal compatibility conditions of orthogonal experimental design was A2B1C1D1(25℃, lucifugal, storage time of 1 h,5% glucose solution), ANOVA results showed that temperature (A), illumination (B) and storage time (C) have significant effects on quercetin and kaempferide contents in Shuxuening injection (P<0.05), however, solvent (D) has no significant effect on them.The temperature (A), illumination (B),storage time (C) and solvent (D) have significant effects on the other five substances (P<0.05).At 0, 1, 4, 6 h, the appearance and pH value of compatible solution (A2B1C1D1) were not significantly changed and the number of insoluble particles in accordance with the relevant provisions of the Chinese Pharmacopoeia with storage time increasing.Conclusion The compatible stability of Shuxuening injection and meglumine adenosine cyclophosphate injection is good under certain conditions, and could use compatibility in clinical therapy.
ABSTRACT
Objective:To investigate the effect of meglumine adenosine cyclophosphate combined with Shenmai injection on the balance of Th1/Th2 cells in the patients with bronchial asthma. Methods:Totally 75 cases of patients with bronchial asthma were ran-domly divided into the treatment group (38 cases) and the control group (37 cases). The control group was treated with the conven-tional therapy, while the treatment group was treated with meglumine adenosine cyclophosphate combined with Shenmai injection by in-travenous infusion additionally for 14 days. The level of Th1/Th2 cells was detected by flow cytometry, and the serum level of IL-10, IL-4 and IFN-γ was detected by enzyme-linked immunosorbent assay ( ELISA) before and after the treatment, and the clinical thera-peutic effect was assessed. Results:①Compared with that before the treatment, the expression level of Th1, Th1/Th2 and IFN-γwas increased in both groups, while the expression level of IL-4 and IL-10 was decreased after the treatment, and the changes in the treat-ment group were more notable than those in the control group (P0. 05). ②The clinical efficiency of the treatment group was 94. 74%, while that of the control group was 83. 78%. The curative effect of the treatment group was better than that of the control group (P<0. 05). Conclusion:Meglumine adenosine cyclophosphate combined with Shenmai injection shows definitely clinical curative effect on bronchial asthma, and the mechanism may be related with regulating the imbalance expression level of Th1/Th2 and inflammatory cytokines.
ABSTRACT
Objective To evaluate the clinical effect of a combination application of meglumine adenosine cyclophosphate and metoprolol in chronic heart failure.Methods Put 50 patients divided into two group randomly:group A(treated group) which has 26 cases and group B(control group) which has 24 cases.Patients of group B will receive a basal treatment in a routine way while patients of group A will receive a basal treatment as well as a additional treatment of meglumine adenosine cyclophosphate and Metoprolol.The clinical effect and changes of heart function will be evaluated in the two group with different treatment after three weeks,left ventricular ejection fraction and left nentricular volume at end-diastole,left nentricular volume at end-systolic were measured by M-mode.Echocardiography before and after curative in two group.Results Patients in the group with a combination application of meglumine adenosine cyclophosphate and metoprolol has a better clinical effect and a improved heart function than the control group.Conclusion A combination application of meglumine adenosine cyclophosphate and metoprolol has good curative effect in treating heart failure.
ABSTRACT
OBJECTIVE:To evaluate the compatible stability of shuxuening injection with meglumine adenosine cyclophosphate Injection.METHODS:The mixture of shuxuening injection and meglumine adenosine cyclophosphate injection in 5% glucose or 0.9% NaCl injection was investigated in respect of its appearance,particles,pH value and absorbability value,respectively using microscope,pH-meter and UV spectrophotometer.RESULTS:No significant change was noted in appearance,particles,pH value and absorbability value for the mixture at 25 ℃ within 6 h after mixing.CONCLUSION:Shuxuening injection was stable in meglumine adenosine cyclophosphate injection and the two drugs can be mixed to use.